These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 25026302)

  • 1. Hepatic overexpression of the prodomain of furin lessens progression of atherosclerosis and reduces vascular remodeling in response to injury.
    Lei X; Basu D; Li Z; Zhang M; Rudic RD; Jiang XC; Jin W
    Atherosclerosis; 2014 Sep; 236(1):121-30. PubMed ID: 25026302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prodomain of Furin Promotes Phospholipid Transfer Protein Proteasomal Degradation in Hepatocytes.
    Yu Y; Lei X; Jiang H; Li Z; Creemers JWM; Zhang M; Qin S; Jin W; Jiang XC
    J Am Heart Assoc; 2018 Apr; 7(9):. PubMed ID: 29680823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FURIN Inhibition Reduces Vascular Remodeling and Atherosclerotic Lesion Progression in Mice.
    Yakala GK; Cabrera-Fuentes HA; Crespo-Avilan GE; Rattanasopa C; Burlacu A; George BL; Anand K; Mayan DC; Corlianò M; Hernández-Reséndiz S; Wu Z; Schwerk AMK; Tan ALJ; Trigueros-Motos L; Chèvre R; Chua T; Kleemann R; Liehn EA; Hausenloy DJ; Ghosh S; Singaraja RR
    Arterioscler Thromb Vasc Biol; 2019 Mar; 39(3):387-401. PubMed ID: 30651003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atherosclerosis-associated hepatic secretion of VLDL but not PCSK9 is dependent on cargo receptor protein Surf4.
    Wang B; Shen Y; Zhai L; Xia X; Gu HM; Wang M; Zhao Y; Chang X; Alabi A; Xing S; Deng S; Liu B; Wang G; Qin S; Zhang DW
    J Lipid Res; 2021; 62():100091. PubMed ID: 34118252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The peroxisome proliferator-activated receptor alpha (PPARalpha) agonist ciprofibrate inhibits apolipoprotein B mRNA editing in low density lipoprotein receptor-deficient mice: effects on plasma lipoproteins and the development of atherosclerotic lesions.
    Fu T; Mukhopadhyay D; Davidson NO; Borensztajn J
    J Biol Chem; 2004 Jul; 279(27):28662-9. PubMed ID: 15123680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms.
    Tavori H; Giunzioni I; Predazzi IM; Plubell D; Shivinsky A; Miles J; Devay RM; Liang H; Rashid S; Linton MF; Fazio S
    Cardiovasc Res; 2016 May; 110(2):268-78. PubMed ID: 26980204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic ABCG5/G8 overexpression reduces apoB-lipoproteins and atherosclerosis when cholesterol absorption is inhibited.
    Basso F; Freeman LA; Ko C; Joyce C; Amar MJ; Shamburek RD; Tansey T; Thomas F; Wu J; Paigen B; Remaley AT; Santamarina-Fojo S; Brewer HB
    J Lipid Res; 2007 Jan; 48(1):114-26. PubMed ID: 17060690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Knockout of Adamts7, a novel coronary artery disease locus in humans, reduces atherosclerosis in mice.
    Bauer RC; Tohyama J; Cui J; Cheng L; Yang J; Zhang X; Ou K; Paschos GK; Zheng XL; Parmacek MS; Rader DJ; Reilly MP
    Circulation; 2015 Mar; 131(13):1202-1213. PubMed ID: 25712206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of hyperlipidemia in LDL receptor-deficient mice having apolipoprotein B100 without the putative receptor-binding sequences.
    Johnson LA; Altenburg MK; Walzem RL; Scanga LT; Maeda N
    Arterioscler Thromb Vasc Biol; 2008 Oct; 28(10):1745-52. PubMed ID: 18617647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic insulin signaling regulates VLDL secretion and atherogenesis in mice.
    Han S; Liang CP; Westerterp M; Senokuchi T; Welch CL; Wang Q; Matsumoto M; Accili D; Tall AR
    J Clin Invest; 2009 Apr; 119(4):1029-41. PubMed ID: 19273907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rosuvastatin Reduces Aortic Sinus and Coronary Artery Atherosclerosis in SR-B1 (Scavenger Receptor Class B Type 1)/ApoE (Apolipoprotein E) Double Knockout Mice Independently of Plasma Cholesterol Lowering.
    Yu P; Xiong T; Tenedero CB; Lebeau P; Ni R; MacDonald ME; Gross PL; Austin RC; Trigatti BL
    Arterioscler Thromb Vasc Biol; 2018 Jan; 38(1):26-39. PubMed ID: 29162602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endothelial lipase promotes the catabolism of ApoB-containing lipoproteins.
    Broedl UC; Maugeais C; Millar JS; Jin W; Moore RE; Fuki IV; Marchadier D; Glick JM; Rader DJ
    Circ Res; 2004 Jun; 94(12):1554-61. PubMed ID: 15117821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective lowering of plasma, LDL, and esterified cholesterol in LDL receptor-knockout mice by adenovirus-mediated gene delivery of ApoB mRNA editing enzyme (Apobec1).
    Teng B; Ishida B; Forte TM; Blumenthal S; Song LZ; Gotto AM; Chan L
    Arterioscler Thromb Vasc Biol; 1997 May; 17(5):889-97. PubMed ID: 9157952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABCA1 overexpression in the liver of LDLr-KO mice leads to accumulation of pro-atherogenic lipoproteins and enhanced atherosclerosis.
    Joyce CW; Wagner EM; Basso F; Amar MJ; Freeman LA; Shamburek RD; Knapper CL; Syed J; Wu J; Vaisman BL; Fruchart-Najib J; Billings EM; Paigen B; Remaley AT; Santamarina-Fojo S; Brewer HB
    J Biol Chem; 2006 Nov; 281(44):33053-65. PubMed ID: 16928680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic Tm6sf2 overexpression affects cellular ApoB-trafficking, plasma lipid levels, hepatic steatosis and atherosclerosis.
    Ehrhardt N; Doche ME; Chen S; Mao HZ; Walsh MT; Bedoya C; Guindi M; Xiong W; Ignatius Irudayam J; Iqbal J; Fuchs S; French SW; Mahmood Hussain M; Arditi M; Arumugaswami V; Péterfy M
    Hum Mol Genet; 2017 Jul; 26(14):2719-2731. PubMed ID: 28449094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of the LDL receptor in apolipoprotein B secretion.
    Twisk J; Gillian-Daniel DL; Tebon A; Wang L; Barrett PH; Attie AD
    J Clin Invest; 2000 Feb; 105(4):521-32. PubMed ID: 10683382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydrogen decreases athero-susceptibility in apolipoprotein B-containing lipoproteins and aorta of apolipoprotein E knockout mice.
    Song G; Tian H; Qin S; Sun X; Yao S; Zong C; Luo Y; Liu J; Yu Y; Sang H; Wang X
    Atherosclerosis; 2012 Mar; 221(1):55-65. PubMed ID: 22209213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic gene transfer of the catalytic subunit of the apolipoprotein B mRNA editing enzyme results in a reduction of plasma LDL levels in normal and watanabe heritable hyperlipidemic rabbits.
    Greeve J; Jona VK; Chowdhury NR; Horwitz MS; Chowdhury JR
    J Lipid Res; 1996 Sep; 37(9):2001-17. PubMed ID: 8895066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice.
    Mullick AE; Fu W; Graham MJ; Lee RG; Witchell D; Bell TA; Whipple CP; Crooke RM
    J Lipid Res; 2011 May; 52(5):885-96. PubMed ID: 21343632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LDL Receptor Regulates the Reverse Transport of Macrophage-Derived Unesterified Cholesterol via Concerted Action of the HDL-LDL Axis: Insight From Mouse Models.
    Cedó L; Metso J; Santos D; García-León A; Plana N; Sabate-Soler S; Rotllan N; Rivas-Urbina A; Méndez-Lara KA; Tondo M; Girona J; Julve J; Pallarès V; Benitez-Amaro A; Llorente-Cortes V; Pérez A; Gómez-Coronado D; Ruotsalainen AK; Levonen AL; Sanchez-Quesada JL; Masana L; Kovanen PT; Jauhiainen M; Lee-Rueckert M; Blanco-Vaca F; Escolà-Gil JC
    Circ Res; 2020 Aug; 127(6):778-792. PubMed ID: 32495699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.